NLRP3 and cancer: Although there is no direct evidence that oridonin induces anticancer activity by inhibiting the NLRP3 inflammasome, its ability to suppress cell proliferation, migration and invasion has been described in ovarian [177], breast [179], osteosarcoma [178] and esophageal [180] cancers.